drugset / Trial / NCT07848295
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1
Not yet recruiting
112 enrolled
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Bristol-Myers Squibb · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986527 in participants with Clear Cell Renal Cell Carcinoma (ccRCC)
Timeline
- Start
- 2026-12-31
- Primary completion
- 2030-10-18
- Completion
- 2031-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986527 | Unknown | — | — |
| Subject | Cabozantinib | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |